Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan DDI Study with Riociguat, Sildenafil, and Rosuvastatin
NCT04211272Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of macitentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Area Under the Plasma Analyte Concentration-time Curve from Time Zero to Infinite Time up to 25 days and Maximum Observed Plasma Analyte Concentration up to 25 days. Started Jan 2020; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04211272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211272.